Raymond James Financial Services Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $14.7M | Buy |
94,415
+4,981
| +6% | +$804K | 0.02% | 689 |
|
|
2024
Q2 | $13.9M | Buy |
89,434
+1,353
| +2% | +$204K | 0.02% | 663 |
|
|
2024
Q1 | $11.9M | Buy |
88,081
+6,575
| +8% | +$871K | 0.02% | 721 |
|
|
2023
Q4 | $11M | Buy |
81,506
+24,771
| +44% | +$3.22M | 0.02% | 712 |
|
|
2023
Q3 | $7.68M | Sell |
56,735
-939
| -2% | -$128K | 0.01% | 821 |
|
|
2023
Q2 | $8.26M | Sell |
57,674
-2,463
| -4% | -$362K | 0.01% | 791 |
|
|
2023
Q1 | $8.35M | Buy |
60,137
+2,439
| +4% | +$328K | 0.02% | 769 |
|
|
2022
Q4 | $7.82M | Sell |
57,698
-1,980
| -3% | -$248K | 0.02% | 758 |
|
|
2022
Q3 | $6.55M | Sell |
59,678
-82
| -0.1% | -$10.4K | 0.01% | 801 |
|
|
2022
Q2 | $7.9M | Sell |
59,760
-657
| -1% | -$86.2K | 0.02% | 726 |
|
|
2022
Q1 | $8.02M | Sell |
60,417
-18,130
| -23% | -$2.17M | 0.02% | 781 |
|
|
2021
Q4 | $9.15M | Sell |
78,547
-831
| -1% | -$97.8K | 0.02% | 727 |
|
|
2021
Q3 | $9.54M | Buy |
79,378
+34,936
| +79% | +$4.07M | 0.02% | 674 |
|
|
2021
Q2 | $5.32M | Sell |
44,442
-5,282
| -11% | -$580K | 0.01% | 949 |
|
|
2021
Q1 | $4.95M | Sell |
49,724
-33,891
| -41% | -$3.41M | 0.01% | 907 |
|
|
2020
Q4 | $8.36M | Sell |
83,615
-811
| -1% | -$85.9K | 0.02% | 634 |
|
|
2020
Q3 | $9.25M | Buy |
84,426
+35,621
| +73% | +$3.96M | 0.03% | 526 |
|
|
2020
Q2 | $5.16M | Sell |
48,805
-12,731
| -21% | -$1.31M | 0.02% | 687 |
|
|
2020
Q1 | $5.5M | Sell |
61,536
-6,405
| -9% | -$603K | 0.02% | 519 |
|
|
2019
Q4 | $6.78M | Buy |
67,941
+19,094
| +39% | +$1.8M | 0.02% | 632 |
|
|
2019
Q3 | $4.35M | Sell |
48,847
-8,952
| -15% | -$776K | 0.02% | 746 |
|
|
2019
Q2 | $4.77M | Sell |
57,799
-4,978
| -8% | -$390K | 0.02% | 700 |
|
|
2019
Q1 | $5.08M | Sell |
62,777
-3,202
| -5% | -$252K | 0.02% | 649 |
|
|
2018
Q4 | $5.01M | Sell |
65,979
-12,582
| -16% | -$983K | 0.03% | 535 |
|
|
2018
Q3 | $6.22M | Sell |
78,561
-4,527
| -5% | -$342K | 0.03% | 567 |
|
|
2018
Q2 | $5.83M | Sell |
83,088
-18,228
| -18% | -$1.31M | 0.03% | 543 |
|
|
2018
Q1 | $7.09M | Buy |
101,316
+15,625
| +18% | +$1.08M | 0.04% | 438 |
|
|
2017
Q4 | $5.95M | Buy |
85,691
+28,834
| +51% | +$1.94M | 0.04% | 473 |
|
|
2017
Q3 | $3.85M | Buy |
56,857
+8,636
| +18% | +$546K | 0.02% | 632 |
|
|
2017
Q2 | $3.29M | Buy |
48,221
+7,549
| +19% | +$493K | 0.02% | 680 |
|
|
2017
Q1 | $2.53M | Sell |
40,672
-7
| -0% | -$407 | 0.02% | 729 |
|
|
2016
Q4 | $2.22M | Sell |
40,679
-4,871
| -11% | -$277K | 0.02% | 725 |
|
|
2016
Q3 | $2.99M | Buy |
45,550
+1,782
| +4% | +$116K | 0.03% | 597 |
|
|
2016
Q2 | $2.64M | Sell |
43,768
-10,393
| -19% | -$604K | 0.03% | 606 |
|
|
2016
Q1 | $3.05M | Buy |
54,161
+5,747
| +12% | +$345K | 0.04% | 470 |
|
|
2015
Q4 | $3.29M | Buy |
48,414
+13,594
| +39% | +$891K | 0.04% | 465 |
|
|
2015
Q3 | $2.22M | Buy |
34,820
+23,504
| +208% | +$1.55M | 0.04% | 487 |
|
|
2015
Q2 | $721K | Buy |
+11,316
| New | +$775K | 0.05% | 398 |
|
|
2013
Q4 | – | Sell |
-57,273
| Closed | -$2.97M | – | 506 |
|
|
2013
Q3 | $2.97M | Sell |
57,273
-29,033
| -34% | -$1.46M | 0.2% | 143 |
|
|
2013
Q2 | $4.08M | Buy |
+86,306
| New | +$4.39M | 0.12% | 199 |
|
Other funds holding AZN
Raymond James Financial Services Advisors's AZN Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its AstraZeneca (AZN) stake by 5.6% in Q3 2024, buying an estimated $804K and bringing the position to 94,415 shares worth $14.7M. The position accounts for 0.02% of the portfolio, ranked #689.
Raymond James Financial Services Advisors first reported a position in AZN in Q2 2013 and has held it in 40 quarters since. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.
- Raymond James Financial Services Advisors held 94,415 shares of AstraZeneca worth $14.7M as of Q3 2024.
- Raymond James Financial Services Advisors bought 4,981 AstraZeneca shares in Q3 2024, an estimated $804K.
- AstraZeneca made up 0.02% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #689 holding.
- Raymond James Financial Services Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 40 quarters since.
- 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.